By Neha MathurFeb 27 2023Reviewed by Danielle Ellis, B.Sc. In a recent study published in the eBioMedicine, researchers performed serial tau imaging with 18F-MK6240 to detect tau accumulation in cognitively unimpaired beta-amyloid negative Alzheimer’s disease patients as well as those with mild cognitive impairment [MCI] who were Aβ+ at baseline.
They evaluated the impact of the AD stage and selected brain regions on estimates of regional rates of tau accumulation. To this end, the team categorized all participants into three clinical groups, CU, MCI, and AD based on prespecified criteria. For instance, they adhered to Winblad et al. and Petersen et al. criteria to assign MCI diagnosis.
Results Drug Discovery eBook Compilation of the top interviews, articles, and news in the last year. Download a free copy The study cohort comprised 184 participants, of which 89, 44, and 51 were CU Aβ−, CU Aβ+, and cognitively impaired Aβ+, respectively. Of all cognitively impaired Aβ+, 26 and 25 had MCI and AD dementia, respectively.
Second, disease-modifying therapies for clearance or slowing of tau accumulation should account for the fact that after attaining very high regional tau levels at baseline, it eventually plateaus or declines in AD Aβ+ participants. Consistent with the tau PET tracer flortaucipir, the regional tau accumulation rates, as depicted in plots of regional tau SUVR, were dependent on baseline tau burden even with 18F-MK6240.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NewsMedical - 🏆 19. / 71 Read more »
Source: NewsMedical - 🏆 19. / 71 Read more »
Source: NECN - 🏆 20. / 71 Read more »